Ipataserib + abiraterone in the treatment of post-chemo mCRPC

One of the more provocative papers to be presented this year at the annual meeting of  the American Society of Clinical Oncology is by De Bono et al. from a large, randomized Phase II trial of a drug called GDC-0068 or ipataserib. … READ MORE …